Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Share-based Compensation data on file, last reported at $16.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $16.0 million, up 12.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.7 million (up 7.68% YoY), and the FY2025 annual result was $59.9 million, up 8.89% from the prior year.
• Share-based Compensation climbed to $16.0 million in Q1 2026 per KYMR's latest filing, from $14.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $16.0 million in Q1 2026 and troughed at $7.9 million in Q1 2022.
• A 5-year average of $12.3 million and a median of $12.0 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 155.7% in 2022, then rose 4.74% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $8.9 million in 2022, then advanced by 22.33% to $10.9 million in 2023, then advanced by 26.62% to $13.8 million in 2024, then rose by 4.74% to $14.5 million in 2025, then grew by 10.75% to $16.0 million in 2026.
• Business Quant data shows KYMR's Share-based Compensation at $16.0 million in Q1 2026, $14.5 million in Q4 2025, and $15.8 million in Q3 2025.